Nature Communications2019ResearchNon-viral Gene Delivery
Francesca Giulimondi, Luca Digiacomo, Daniela Pozzi, Sara Palchetti, Elisabetta Vulpis, Anna Laura Capriotti, Riccardo Zenezini Chiozzi, Aldo Laganà, Heinz Amenitsch, Laura Masuelli, Giovanna Peruzzi, Morteza Mahmoudi, Isabella Screpanti, Alessandra Zingoni
Liposome clinical translation is limited by opsonisation and rapid clearance by immune cells. Although the protein corona is recognised as the liposome’s “biological identity,” it was unclear whether pre-adsorbed corona proteins could help liposomes avoid capture by circulating leukocytes in whole blood and thereby…
Read the article →Biomaterials Science2019ResearchNon-viral Gene Delivery
Brynn R. Olden, Emmeline Cheng, Yilong Cheng, Suzie H. Pun
T cells are an important target for ex vivo gene delivery and editing, but most commercial reagents cannot transfect them and cationic polymers show only moderate success. The specific intracellular barriers limiting non-viral gene delivery to human T cells are poorly understood, hindering rational polymer design…
Read the article →American Journal of Translational Research (Am J Transl Res)2019ResearchNon-viral Gene Delivery
CAR-T cell therapy relies mainly on retroviral/lentiviral vectors, which carry risks of carcinogenicity and complex manufacturing. PiggyBac transposon systems offer a safer, simpler non-viral alternative for stable transgene expression, but primary T lymphocytes are difficult to transfect efficiently. A polymeric…
Read the article →Nano Letters2019ResearchNon-viral Gene Delivery
Yuhang Jiang, Qiao Lu, Yongheng Wang, Emily Xu, Alison Ho, Priya Singh, Yifei Wang, Zhaozhong Jiang, Fan Yang, Gregory T. Tietjen, Peter Cresswell, W. Mark Saltzman
Endosomal escape is a key but poorly quantified step for intracellular nucleic acid delivery. Existing methods are low-throughput, indirect, or fail to distinguish endosomal disruption from actual cytosolic cargo delivery. A reliable, sensitive method is needed to rationally optimise polymeric mRNA delivery vehicles…
Read the article →Acta Biomaterialia2019ResearchNon-viral Gene Delivery
Zuoying Yuan, Pengfei Wei, Yiqian Huang, Wenxin Zhang, Fuyu Chen, Xu Zhang, Jianping Mao, Dafu Chen, Qing Cai, Xiaoping Yang
Magnesium ions (Mg²⁺) promote bone regeneration, but their effects are strongly concentration-dependent: too little has minimal effect, while excess Mg²⁺ can impair osteoblast activity and bone metabolism. There is no well-established bone tissue engineering scaffold that precisely controls local Mg²⁺ release…
Read the article →Molecular Pharmaceutics2019ResearchNon-viral Gene Delivery
Wilson, D. R., Rui, Y., Siddiq, K., Routkevitch, D., & Green, J. J. (2019).
Nonviral gene delivery remains limited by low transfection efficacy, especially under physiological serum conditions and at low nanoparticle doses. Although linear poly(β-amino ester)s (PBAEs) are effective, branching structure had not been systematically evaluated in well-defined PBAE-like poly(ester amine) systems…
Read the article →International Journal of Pharmaceutics (inferred; the supplied PDF is marked “2019ResearchNon-viral Gene Delivery
Yingqi Xu, Dingxin Liu, Jie Hu, Peirong Ding, Meiwan Chen
Triple-negative breast cancer (TNBC) lacks effective targeted therapy. Nonviral co-delivery of an anticancer drug and a therapeutic gene may improve treatment, but efficient tumour-targeted co-delivery remains challenging. TRAIL has shown limited clinical benefit alone, and embelin (EMB) can inhibit XIAP to promote…
Read the article →2019ReviewNon-viral Gene Delivery
Majumder J, Et Al.
Conventional systemic drug administration suffers from low site-specific bioavailability, unfavourable biodistribution, poor target accumulation, and adverse side effects. There is a need for carrier-based systems that enable localised and targeted delivery, improve therapeutic efficacy, and reduce toxicity…
Read the article →Cancer Letters2019ReviewNon-viral Gene Delivery
Mukalel Aj, Riley Rs, Zhang R, Mitchell Mj.
Nucleic acid therapeutics—DNA, mRNA, and CRISPR/Cas9 genome editing systems—hold significant potential for cancer immunotherapy but face major delivery barriers, including rapid in vivo degradation, poor cellular uptake, required nuclear entry, and toxicity in healthy tissues. Nanoparticle delivery systems are being…
Read the article →2019ReviewNon-viral Gene Delivery
Jin Q, Deng Y, Chen X, Ji J.
Ideal cancer nanomedicines need a stealth surface for prolonged circulation and tumour accumulation, but stealth surfaces often hinder cellular uptake. Conversely, cationic or targeting-ligand surfaces enhance uptake but cause rapid clearance and off-target interactions. This review addresses the central conflict…
Read the article →Biomaterials2019ReviewNon-viral Gene Delivery
Zhao W, Hou X, Vick Og, Dong Y.
Genetic and rare diseases (GARDs) affect more than 350 million patients worldwide, and many lack effective treatments. RNA-based therapeutics—siRNA, mRNA, miRNA, lncRNA, and RNA-containing genome editing systems—are promising, but naked RNA has poor cellular penetration, is degraded in biological fluids, and does not…
Read the article →2019ReviewNon-viral Gene Delivery
Gheibi Hayat Sm, Bianconi V, Pirro M, Sahebkar A.
Biomaterials and nanoparticles (NPs) used for medical purposes often trigger immune recognition, inflammation, and rapid clearance by the reticuloendothelial system (RES)/mononuclear phagocyte system (MPS). PEGylation and cell-membrane camouflaging are common stealth strategies, but they have limitations, including…
Read the article →Biochimie2019ReviewDrug Delivery
Aqeel Ahmad, Javed Masood Khan, Shafiul Haque
Endosomal escape remains the rate-limiting step for efficient gene and drug delivery using nanoparticles (NPs). Despite continuous advancements, most NPs internalised via endocytic pathways are degraded by hydrolytic enzymes in lysosomes, severely limiting therapeutic efficacy. There is an unmet need to…
Read the article →Pharmaceutics (MDPI)2019ReviewNon-viral Gene Delivery
Run Ni, Ruoyu Fang, And Ying Chau
While many reviews have systematically covered different types of formulation materials for gene delivery, a parallel comparison of different formulation materials together with an analysis of the correlation between their material properties and nucleic acid delivery functions has not been conducted. Understanding…
Read the article →Bioconjugate Chemistry (likely; based on formatting and page range)2019ReviewNon-viral Gene Delivery
Samuel A. Smith, Laura I. Selby, Angus P. R. Johnston, And Georgina K. Such
Many emerging therapies require delivery of biological cargo into the cytosol, but nanoparticle delivery systems are hindered by entrapment and degradation in the endo/lysosomal pathway. Endosomal escape remains a rate-determining step for non-viral delivery. The review highlights the need for greater understanding…
Read the article →Biomaterials Research2019ReviewDrug Delivery
Dhrisya Chenthamara, Sadhasivam Subramaniam, Sankar Ganesh Ramakrishnan, Swaminathan Krishnaswamy, Musthafa Mohamed Essa, Feng-Huei Lin, And M. Walid Qoronfleh
Despite enormous strides in nanotechnology research and development, it is often confusing for beginners to make an informed choice regarding the nanocarrier system and its potential applications. There is a need to provide a comprehensive overview of commonly used nanomaterials, their core properties, surface…
Read the article →Biomaterials Science2019ReviewNon-viral Gene Delivery
Alidha Gafur, Natalia Kristi, Ali Maruf, Guixue Wang, And Zhiyi Ye
Despite decades of nanomedicine development for tumour therapy, less than 1% of systemically administered nanocarriers (NCs) accumulate in solid tumours. This is largely due to protein corona formation during blood circulation, which accelerates clearance and masks targeting ligands. Stealthy (neutral/negatively…
Read the article →Chemistry and Physics of Lipids2019ReviewNon-viral Gene Delivery
Scheideler M, Vidakovic I, Prassl R
miRNAs can regulate about 60% of protein-coding genes and enable targeting of previously “undruggable” proteins and diseases, but their clinical use is limited by nuclease degradation, poor tissue targeting, inefficient cellular uptake, and inadequate cytosolic release. Lipid nanocarriers are a versatile…
Read the article →Journal of Pharmaceutical Investigation2019ReviewDrug Delivery
PLA and PLGA are FDA-approved, biodegradable polymers widely used for micro- and nanoparticle drug delivery, but their clinical performance depends on biocompatibility, degradation behaviour, and drug-release control. This review addresses the need to understand PLA/PLGA tissue responses, degradation pathways…
Read the article →Molecules2019ReviewNon-viral Gene Delivery
Thomas, T. J.; Tajmir-Riahi, H.-A.; Pillai, C. K. S
Gene therapy requires efficient delivery of genetic material, but viral vectors carry risks of immunogenicity, toxicity, and cancer formation. Cationic polymers such as polyethyleneimine (PEI) can condense DNA and facilitate delivery, but their lack of biodegradation causes significant toxicity due to polymer…
Read the article →Journal of King Saud University – Science2019ReviewDrug Delivery
Venditti, I
Polymeric nanocarriers such as dendrimers, micelles, nanoparticles, nanogels, nanocapsules, and vesicles are widely investigated for drug delivery, but their morphology, surface chemistry, and functionalisation strongly influence drug loading, controlled release, and targeting. This review addresses the need for a…
Read the article →Journal of Controlled Release2019ReviewNon-viral Gene Delivery
Cordeiro, R. A.; Serra, A.; Coelho, J. F. J.; Faneca, H
Gene therapy requires safe and effective delivery vectors. PBAEs are biodegradable cationic polymers with excellent gene delivery properties, but a comprehensive and critical overview of their use as gene carriers is lacking. This review provides the first comprehensive and critical overview of PBAE-based gene…
Read the article →Nanoscale2019ReviewDrug Delivery
Ferrari, R.; Sponchioni, M.; Morbidelli, M.; Moscatelli, D
Many polymer-based nanoparticle formulations fail before or during clinical trials. This review identifies the key checkpoints a nanocarrier must satisfy after intravenous injection — biocompatibility, drug loading/release, storage stability, biodistribution, target selectivity, cellular internalisation, and…
Read the article →Nature Reviews Drug Discovery2019ReviewNon-viral Gene Delivery
Ekliadious, I.; Colson, Y. L.; Grinstaff, M. W
Polymer–drug conjugates have achieved clinical success, especially PEG–protein conjugates, but translation of many conjugates—particularly polymer–small-molecule anticancer therapeutics—remains limited. This review addresses the need for rational design, better understanding of in vivo barriers, and identification of…
Read the article →